Clinuvel Pharmaceuticals Limited (CUVL)

NASDAQ: CUVL · Real-Time Price · USD

4.910

-0.160 (-3.16%)

At close: Nov 2, 2026, 4:00 PM EST

4.910

0.00 (0.00%)

After-hours: Nov 2, 2026, 4:10 PM EST

Clinuvel Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is July - June.

Millions USD. Fiscal year is Jul - Jun.

Total Valuation

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov '26 Nov 2, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Market Capitalization	253	359	341	514	588	506
Market Cap Growth	-	5.14%	-33.59%	-12.65%	16.31%	-55.55%
Enterprise Value	77	198	212	398	495	438
Last Close Price	4.91	7.27	6.75	9.69	11.81	10.11

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov '26 Nov 2, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
PE Ratio	10.50	15.28	14.38	21.60	28.87	35.14
PS Ratio	3.89	5.51	5.48	8.73	11.28	11.16
PB Ratio	1.34	1.90	2.16	3.79	5.37	5.84
P/TBV Ratio	1.34	1.90	2.16	3.80	5.37	5.85
P/FCF Ratio	10.24	14.68	12.75	24.46	24.62	18.61
P/OCF Ratio	9.80	14.05	12.66	20.77	23.93	18.40

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov '26 Nov 2, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
EV/Sales Ratio	1.19	3.04	3.40	6.76	9.50	9.68
EV/EBITDA Ratio	2.73	6.95	7.68	12.09	16.71	17.68
EV/EBIT Ratio	2.76	7.05	7.82	12.28	16.86	17.89
EV/FCF Ratio	3.14	8.09	7.91	18.95	20.73	16.13

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov '26 Nov 2, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Debt / Equity Ratio	0.01	0.01	0.00	0.00	0.01	0.01
Debt / EBITDA Ratio	0.05	0.05	0.01	0.02	0.02	0.03
Debt / FCF Ratio	0.06	0.06	0.01	0.03	0.03	0.03
Net Debt / Equity Ratio	-0.92	-0.92	-0.93	-0.90	-0.95	-0.96
Net Debt / EBITDA Ratio	-6.08	-6.08	-5.32	-3.71	-3.50	-3.34
Net Debt / FCF Ratio	-7.08	-7.08	-5.48	-5.81	-4.34	-3.05
Asset Turnover	0.33	0.33	0.38	0.42	0.46	0.52
Inventory Turnover	2.01	2.01	1.52	0.77	1.33	3.69
Quick Ratio	14.34	14.34	9.24	8.33	7.02	10.03
Current Ratio	14.81	14.81	9.66	8.81	7.44	10.24
Return on Equity (ROE)	13.21%	13.21%	16.30%	19.39%	21.09%	18.62%
Return on Assets (ROA)	8.94%	8.94%	10.26%	14.29%	16.34%	17.60%
Return on Invested Capital (ROIC)	126.71%	144.24%	155.46%	236.84%	336.03%	-
Return on Capital Employed (ROCE)	14.70%	14.70%	16.90%	23.60%	26.20%	27.30%

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Nov '26 Nov 2, 2026	Jun '26 Jun 30, 2026	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Earnings Yield	9.52%	6.54%	6.95%	4.63%	3.46%	2.84%
FCF Yield	9.77%	6.81%	7.84%	4.09%	4.06%	5.38%
Dividend Yield	0.58%	0.49%	0.48%	0.33%	0.28%	0.27%
Payout Ratio	6.04%	7.39%	6.92%	6.93%	6.46%	5.92%
Buyback Yield / Dilution	-0.73%	-0.73%	1.27%	1.52%	-0.08%	-1.26%
Total Shareholder Return	-0.15%	-0.24%	1.75%	1.85%	0.20%	-0.99%

SEC Filings: 10-K · 10-Q